Abstract
The primary reason for studying drugs that affect lipid metabolism is, of course, the hope of generating useful pharmacologic agents. In addition, however, studies of new agents have taught us important lessons regarding normal lipid and lipoprotein metabolism. In this presentation I wish to take up three “case histories” in the latter category: (1) bile acid sequestrants; (2) inhibitors of cholesterol biosynthesis, particularly inhibitors of HMG CoA reductase; (3) probucol.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Levy R, Langer T (1972) Hypolipodemic drugs and lipoprotein metabolism. Adv Exp Med Biol 26:155–163
Slater HR, Packard CJ, Bicker S, Shepherd J (1980) Effects of cholestyramine on receptor-mediated plasma clearance and tissue uptake of human low density lipoproteins in the rabbit. J Biol Chem 265:10210–10213
Kovanen P, Bilheimer DW, Goldstein JL, Jaramillo JJ, Brown M (1981) Regulatory role for hepatic low density lipoprotein receptors in vivo in the dog. Proc Natl Acad Sci USA 78: 1194–1198
Hui D, Innerarity TL, Mahley W (1981) Lipoprotein binding to canine hepatic membranes. J Biol Chem 256:5646–5655
Brown MS, Kovanen PT, Goldstein JL (1981) Regulation of plasma cholesterol by lipoprotein receptors. Science 212:626–635
Witztum JL, Schonfeld G, Weidman SW, Giese WE, Dillingham MA (1979) Bile sequestrant therapy alters the compositions of low-density and high-density lipoproteins. Metabolism 28:221–229
Witztum JL, Young SG, Elam RL, Carew TE, Fisher M (1985) Cholestyramine-induced changes in low density lipoprotein composition and metabolism. I. Studies in the guinea pig. J Lipid Res 26:92–103
Phair RD, Hammond MG, Bowden JA, Fried M, Fisher WR, Berman M (1975) Federation Proc 34:2263–2270
Cottet J, Mathivat A, Redel J (1954) Etude thérapeutique d’un hypo choiestérolémiant de synthèse: l’acide phényl-éthyl-acétique. Presse Med 62:939–941
Steinberg D, Fredrickson DA (1956) Inhibitors of cholesterol biosynthesis and the problem of hypercholesterolemia. Ann NY Acad Sci 64:579–589
Steinberg D (1962) Chemotherapeutic approaches to hyperlipidemia. Adv Pharmacol 1: 59–159
Steinberg D, Avigan J (1961) Inhibitors of cholesterol biosynthesis with special reference to the mechanism of action of MER-29. In: Garattini S, Saoletto R (eds) Drugs affecting lipid metabolism. Academic Press, London New York, pp 132–143
Endo A, Tsujita A, Kuroda M, Tanzawa K (1977) Inhibition of cholesterol synthesis in vitro and in vivo by ML-236A and ML-236B, competitive inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Eur J Blochem 77:31–36
Alberts AW, Chen J, Kuron G (1980) Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme. A reductase and a cholesterol-lowering agent. Proc Natl Acad Sci USA 77:3957–3961
Yamamoto A, Sudo H, Endo A (1980) Therapeutic effects of ML-236B in primary hypercholesterolemia. Atherosclerosis 35:259–266
Illingworth DR (1984) Mevinolin plus colestipol in therapy for severe heterozygous familial hypercholesterolemia. Ann Int Med 101:598–604
Mabuchi H, Sakai T, Sakai Y (1983) Reduction of serum cholesterol in heterozygous patients with familial hypercholesterolemia: additive effects of compactin and cholestyramine. N Engl J Med 308:609–613
Nestel PJ, Billington T (1981) Effects of probucol on low density lipoproteins removal and high density lipoprotein synthesis. Atherosclerosis 38:203–209
Kesaniemi YA, Grundy SM (1984) Influence of probucol on cholesterol and lipoprotein metabolism in man. J Lipid Res 25:780–790
Baker SG, Joffe BI, Mendelssohn D, Seftel HG (1982) Treatment of homozygous familial hypercholesterolemia with probucol. S Sfr Med J 62:7–11
Yamomoto A, Matsuzawa Y, Kishino B, Hayashi R, Hirobe K, Kikkawa T (1983) Effects of probucol on homozygous cases of familial hypercholesterolemia. Atherosclerosis 48:157–166
Naruszewicz M, Carew TE, Pittman RC, Witztum JL, Steinberg D (1984) A novel mechanism by which probucol lowers low density lipoprotein levels demonstrated in the LDL receptor-deficient rabbit. J Lipid Res 25:1206–1213
Steinbrecher UP, Witztum JL, Kesaniemi YA, Elam RL (1983) Comparison of glucosylated low density lipoprotein with methylated or cyclohexane-treated low density lipoprotein in the measurement of receptor-independent low density lipoprotein catabolism. J Clin Invest 71:960–964
Steinberg D (1987) Current theories of the pathogenesis of atherosclerosis. In: Steinberg D, Olefsky J (eds) Hypercholesterolemia and atherosclerosis. Churchill Livingstone, New York, pp 5–23
Goldstein JL, Ho YK, Basu JK, Brown MS (1979) Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. Proc Natl Acad Sci USA 76:333–337
Steinbrecher UP, Parthasarathy S, Leake DS, Witztum JL, Steinberg D (1984) Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids. Proc Natl Acad Sci USA 81:3883–3387
Parthasarathy S, Young SG, Witztum JL, Pittman RC, Steinberg D (1986) Probucol inhibits oxidative modification of low density lipoprotein. J Clin Invest 77:641–644
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1987 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Steinberg, D. (1987). Hypocholesterolemic Drugs and Lipoprotein Metabolism. In: Paoletti, R., Kritchevsky, D., Holmes, W.L. (eds) Drugs Affecting Lipid Metabolism. Proceedings in Life Sciences. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-71702-4_13
Download citation
DOI: https://doi.org/10.1007/978-3-642-71702-4_13
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-71704-8
Online ISBN: 978-3-642-71702-4
eBook Packages: Springer Book Archive